Kaplan Fox Investigates Potential Securities Violations at Cellebrite

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Cellebrite DI Ltd. (CLBT), a company listed on the NASDAQ. The law firm, known for its expertise in complex litigation, is urging investors who have suffered losses or possess relevant information to contact them.

Cellebrite, a provider of mobile device forensic and communication analysis software, recently reported its second-quarter financial results, revealing a significant shortfall in its revenue. The company reported total Annual Recurring Revenue (ARR) of $507.8 million, falling short of its previous projection range of $510 million to $513 million. Additionally, Cellebrite cut its full-year annual recurring revenue guidance by approximately $15 million at the midpoint, citing delays due to a foreign entity permit requirement that affects cloud technology.

These financial revelations were accompanied by an abrupt change in leadership, with CEO Tom Hogan being replaced by Shiv Ramji as of August 13, 2026. The unexpected CEO transition, coupled with the revenue shortfall, led to a significant drop in Cellebrite's stock price, which fell by $4.45 per share, or 29%, to close at $10.80 per share.

Kaplan Fox & Kilsheimer LLP, founded in 1956, has a long history of representing public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. The firm has secured numerous landmark cases, including a $2.425 billion recovery for Bank of America shareholders and an $800 million settlement for the Arkansas Teacher Retirement System.